FUNDACION PARA LA INVESTIGACION MEDICA APLICADA Date: 06 sep
Location: Pamplona
Position OverviewAn FPI Scholarship is offered to carry out a doctoral thesis in the Combined Strategies for Translational Immunotherapy Group of Immunology Program framed in project PID2023-147515OB-I00 funded by MCIU/AEI/10.13039/*texto oculto*033 and FSE+ entitled:
Synergistic combinations for cancer Immunotherapy based on agonist immunotherapy agents and interference with pro-tumoral inflammation (SynerCombIT) Transformative opportunities in the field of cancer immunotherapeutics usually stem from combinations involving agents of immunotherapy among themselves or in synergistic combinations with either chemotherapy or antiangiogenics. Such combined treatment approaches have already revolutionized the treatment of a good number of solid malignancies becoming the best treatment options for patients. However, multiple lines of evidence show that there exist inflammatory responses in cancer-bearing hosts that act to curtail the efficacy of immunotherapy.
Over the recent years, we have performed innovative preclinical and clinical research with CD137 (4-1BB) agonists, cytokine-based approaches, local immunotherapies including TLR agonists and RNA-engineered T-cell transfer. The overarching goal of SynerCombIT is to use these novel approaches in conjunction with the interference of protumoral inflammatory mediators, testing such therapeutic approaches against difficult to treat mouse cancer models to gauge their efficacy, while interrogating the key mechanisms underlying the synergistic effects.
SynerCombIT plans to interfere with neutrophil chemoattractant and NETosis in combination with other immunotherapy approaches. In collaboration with various leading pharmaceutical companies, we will also test the most promising combinatorial strategies on explanted tissue cultures from freshly excised human tumors and in immunologically humanized mouse models bearing human tumor xenografts.
To achieve its objectives the project will rely on genetically modified mouse strains (with TCR or conditional fluorescent transgenes, DTR-depletable of leukocyte subsets, immunodeficient, etc), multiplex tissue immunofluorescence, transcriptomics, multiphoton intravital microscopy, mRNA transient gene-transfer and a variety of in-vivo and ex-vivo functional immune assessments.
The opportunity envisioned by SynerCombIT comes from established strategies to tamper with protumor inflammatory mediators that can actually be repurposed from clinically successful approaches to treat autoimmune conditions and systemic inflammation. This project proposal, as based on solid preliminary data, is preclinical but endowed with a truly translational ambition to benefit cancer patients in liaison with the pharmaceutical industry. SynerCombIT will deliver efficacious synergist treatment combinations, whose mechanisms will be meticulously studied with state-of-the-art methodologies.
Candidate ProfileThe selected candidate will work in a dynamic and collaborative environment, participating in an innovative project that addresses fundamental questions in the field of immunotherapy.
Contract Details4-year predoctoral contract in the Center for Applied Medical Research.
For more information: El anuncio original lo puedes encontrar en Kit Empleo: Kit Empleo
#J-18808-Ljbffr
